Increased interleukin-2 serum levels were associated with psychopathological symptoms and cognitive deficits in treatment-resistant schizophrenia

Schizophrenia Research

Volumn 169, Issue 1-3, 2015, Pages 16-21

  Tan, Yunlong ^a   Li, Yanli ^a   Tan, Shuping ^a   Wang, Zhiren ^a   Yang, Fu De ^a   Cao, Bo ^b   Zunta Soares, Giovana B ^b   Soares, Jair C ^b   Zhang, Xiang Yang ^a,b  

^a PEKING UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Clinical symptom; Cytokines; Immune; Interleukin 2; Schizophrenia

Indexed keywords

INTERLEUKIN 2; BIOLOGICAL MARKER; IL2 PROTEIN, HUMAN; NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEBEPHRENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESIDUAL SCHIZOPHRENIA; SCHIZOPHRENIA; SEX DIFFERENCE; SYMPTOMATOLOGY; BLOOD; BLOOD ANALYSIS; CHRONIC DISEASE; COGNITION DISORDERS; COHORT ANALYSIS; COMPLICATION; DRUG RESISTANCE; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; REGRESSION ANALYSIS;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIOMARKERS; BLOOD CHEMICAL ANALYSIS; CHRONIC DISEASE; COGNITION DISORDERS; COHORT STUDIES; DRUG RESISTANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84953743894     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.10.038     Document Type: Article

References (50)

1. Al-Amin M.M., Nasir Uddin M.M., Mahmud Reza H. Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures. Clin. Psychopharmacol. Neurosci. 2013, 11(3):144-151.
2. Altamura A.C., Pozzoli S., Fiorentini A., Dell'osso B. Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 42:63-70.
3. An H.M., Tan Y.L., Shi J., Wang Z.R., Soars J.C., Wu J.Q., Yang F.D., Huang X.F., Zhang X.Y. Altered IL-2, IL-6 and IL-8 serum levels in schizophrenia patients with tardive dyskinesia. Schizophr. Res. 2015, 162(1-3):261-268.
4. Asevedo E., Rizzo L.B., Gadelh A., Mansur R.B., Ota V.K., Berberian A.A., Scarpato B.S., Teixeira A.L., Bressan R.A., Brietzke E. Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. Physiol. Behav. 2014, 129:194-198.
5. Craddock R.M., Lockstone H.E., Rider D.A., Wayland M.T., Harris L.J., McKenna P.J., Bahn S. Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms. PLoS One 2007, 2(8).
6. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav. Immun. 2006, 20(6):532-545.
7. Freudenreich O., Brockman M.A., Henderson D.C., Evins A.E., Fan X., Walsh J.P., Goff D.C. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Res. 2010, 176(2-3):99-102.
8. Girgis R.R., Kumar S.S., Brown A.S. The cytokine model of schizophrenia: emerging therapeutic strategies. Biol. Psychiatry 2014, 75(4):292-299.
9. Guo J., Liu C., Wang Y., Feng B., Zhang X. Role of T helper lymphokines in the immune-inflammatory pathophysiology of schizophrenia: systematic review and meta-analysis. Nord. J. Psychiatry 2015, 69(5):364-372.
10. Howes O., McCutcheon R., Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J. Psychopharmacol. 2015, 29(2):97-115.
11. Hoyer K.K., Dooms H., Barron L., Abbas A.K. Interleukin-2 in the development and control of inflammatory disease. Immunol. Rev. 2008, 226:19-28.
12. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
13. Khandaker G.M., Dantzer R. Is there a role for immune-to-brain communication in schizophrenia?. Psychopharmacology 2015, ([Epub ahead of print]).
14. Khandaker G.M., Cousins L., Deakin J., Lennox B.R., Yolken R., Jones P.B. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2015, 2(3):258-270.
15. Kim Y.K., Kim L., Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr. Res. 2000, 44:165-175.
16. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry 2000, 157:683-694.
17. Lacosta S., Merali Z., Anisman H. Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors, and anxiety. Behav. Neurosci. 1999, 113:1030-1041.
18. Lacosta S., Merali Z., Anisman H. Central monoamine activity following acute and repeated systemic interleukin-2 administration. Neuroimmunomodulation 2000, 8(2):83-90.
19. Liao W., Lin J.X., Leonard W.J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38:13-25.
20. Lin A., Kenis G., Bignotti S., Tura G.J., DeJong R., Bosmans E., Pioli R., Altamura C., Scharpe S., Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 1998, 32:9-15.
21. Lisman J. Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia?. Curr. Opin. Neurobiol. 2012, 22(3):537-544.
22. Liu H., Kang Y., Liang J., Li C., Xiu M., Chen D., Yang F., Wang F., Wu G., Haile C.N., Kosten T.A., Kosten T.R., Zhang X.Y. Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia. Psychiatry Res. 2012, 198:329-331.
23. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G., Pioli R., Boin F., Kenis G., Bosmans E., de Jongh R., Lin A., Racagni G., Altamura C.A. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur. Neuropsychopharmacol. 2000, 10:119-124.
24. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
25. Müller N. Immunology of schizophrenia. Neuroimmunomodulation 2014, 21(2-3):109-116.
26. Muller N., Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res. 2006, 10:131-148.
27. Myint A.M., Schwarz M.J., Steinbusch H.W., Leonard B.E. Neuropsychiatric disorders related to interferon and interleukins treatment. Metab. Brain Dis. 2009, 24:55-68.
28. Na K.S., Jung H.Y., Kim Y.K. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014, 48:277-286.
29. Naudin J., Capo C., Giusano B., Mege J.L., Azorin J.M. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?. Schizophr. Res. 1997, 26:227-233.
30. Nemni R., Iannaccone S., Quattrini A., Smirne S., Sessa M., Lodi M., Erminio C., Canal N. Effect of chronic treatment with recombinant interleukin-2 on the central nervous system of adult and old mice. Brain Res. 1992, 591:248-252.
31. Paul-Samojedny M., Owczarek A., Kowalczyk M., Suchanek R., Palacz M., Kucia K., Fila-Daniłow A., Borkowska P., Kowalski J. Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFα) gene polymorphisms with paranoid schizophrenia in a Polish population. J. Neuropsychiatr. Clin. Neurosci. 2013, 25:72-82.
32. Petitto J.M., Huang Z. Cloning the full-length IL-2/15 receptor-β cDNA sequence from mouse brain: evidence of enrichment in hippocampal formation neurons. Regul. Pept. 2001, 98:77-87.
33. Petitto J.M., McNamara R., Gendreau P.L., Huang Z., Jackson A. Impaired learning and memory and altered hippocampal neurodevelopment resulting from IL-2 gene deletion. J. Neurosci. Res. 1999, 56:441-446.
34. Petitto J.M., Meola D., Huang Z. Interleukin-2 and the brain: dissecting central versus peripheral contributions using unique mouse models. Methods Mol. Biol. 2012, 934:301-311.
35. Petitto J.M., Huang Z., Meola D., Ha G.K., Dauer D. Interleukin-2 and the septohippocampal system: intrinsic actions and autoimmune processes relevant to neuropsychiatric disorders. Methods Mol. Biol. 2012, 829:433-443.
36. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63:801-808.
37. Rodriguez-Jimenez R., Bagney A., Mezquita L., Martinez-Gras I., Sanchez-Morla E., Mesa N., Ibanez M., Diez-Martin J., Jimenez-Arriero M., Lobo A., Santos J., Palomo T., PARG Cognition and the five-factor model of the Positive and Negative Syndrome Scale in schizophrenia. Schizophr. Res. 2013, 143(1):77-83.
38. Schwarz M.J., Krönig H., Riedel M., Dehning S., Douhet A., Spellmann I., Ackenheil M., Möller H.J., Müller N. IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2006, 256(2):72-76.
39. Singh B., Bera N.K., Nayak C.R., Chaudhuri T.K. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 2009, 47(1):1-5.
40. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med. Hypotheses 1995, 95(45):135-141.
41. Tomasik J., Rahmoune H., Guest P.C., Bahn S. Neuroimmune biomarkers in schizophrenia. Schizophr. Res. 2014, (pii: S0920-9964(14)00382-X. doi: 10.1016/j.schres.2014.07.025 [Epub ahead of print]).
42. Tourjman V., Kouassi É., Koué M.È., Rocchetti M., Fortin-Fournier S., Fusar-Poli P., Potvin S. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr. Res. 2013, 151(1-3):43-47.
43. Wallwork R.S., Fortgang R., Hashimoto R., Weinberger D.R., Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr. Res. 2012, 137(1-3):246-250.
44. Watkins C.C., Andrews S.R. Clinical studies of neuroinflammatory mechanisms in schizophrenia. Schizophr. Res. 2015, (pii: S0920-9964(15)00362-X. doi: 10.1016/j.schres.2015.07.018. [Epub ahead of print]).
45. Xiong P., Zeng Y., Wan J., Xiaohan D.H., Tan D., Lu J., Xu F., Li H.Y., Zhu Z., Ma M. The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia. Psychiatry Res. 2011, 189:72-76.
46. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y. Decreased production of interleukin-2 (IL-2), IL-2 secreting cells and CD4+ cells in medication-free patients with schizophrenia. J. Psychiatr. Res. 2002, 36:331-336.
47. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr. Res. 2002, 57(2-3):247-258.
48. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry 2004, 65:940-947.
49. Zhang X.Y., Cao L.Y., Song C., Wu G.Y., Chen da C., Qi L.Y., Wang F., Xiu M.H., Chen S., Zhang Y., Lu L., Kosten T.A., Kosten T.R. Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics. Psychopharmacology 2008, 201:383-389.
50. Zhang X.Y., Liang J., Chen da C., Xiu M.H., Yang F.D., Kosten T.A., Kosten T.R. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology 2012, 222(2):277-284.